Baxa Corporation Signs Co-Marketing Agreement with VIASYS MedSystems for Specialty Enteral Feeding Products
Share:
ENGLEWOOD, Colo., Jan. 18: Baxa Corporation has signed an exclusive co-marketing agreement with VIASYS MedSystems Inc., a subsidiary of VIASYS Healthcare Inc. (NYSE:VAS) to cross-promote their respective enteral feeding products for neonates. The agreement covers the Baxa Exacta-Med(R) Enteral Syringes and the VIASYS CORFLO(R) Anti-IV Enteral Feeding System, which combine to form a system intended to reduce the wrong-route administration of non-IV fluids for neonatal and pediatric patients.
The first syringes designed only for enteral feeding, Baxa Exacta-Med Enteral Syringes are available individually packaged in 20, 35 and 60 mL sizes. The syringes feature a unique tip that cannot connect to a luer needle or needleless IV system. Unique coloring and markings make them the safer choice for enteral fluid drug delivery, particularly in pediatric and neonatal applications where the majority of the oral and enteral doses are provided through a gastric tube.
The CORFLO Anti-IV Enteral Feeding System promotes safe, non-luer connections for enteral feeding of neonatal and pediatric patients. The system's non-luer connections are designed to accept only a dedicated enteral syringe tip. In addition to the Anti-IV System, VIASYS MedSystems provides a complete range of enteral access devices to fit specific clinical needs in the hospital, nursing home, and home care markets. "The agreement," notes Baxa Product Manager Katie Calabrese, "formalizes the strong relationship that Baxa and VIASYS have built over the past few months in addressing the issue of tubing misconnections in our most critical patients - neonates. Both companies are focused on developing a safe alternative to current practice that reduces wrong-route errors. Together, we can offer a complete, dedicated system."
Baxa Corporation focuses on providing technology to health-system pharmacies that improves patient safety, reduces the risk of medication errors and facilitates compliance to USP, JCAHO and other regulatory requirements. Baxa introduced the Enteral Syringes at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting held December 3-8, 2006, in Anaheim, California.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide. Further information is available at www.baxa.com.
About VIASYS Healthcare Inc.
VIASYS Healthcare Inc. is a global, research-based medical technology company focused on respiratory, neurology, medical disposable and orthopedic products. VIASYS products are marketed under well-recognized trademarks including, among others, AVEA(R), BEAR(R), BIRD(R), CORFLO(R), CORPAK(R), CORTRAK(R), EME(R), GRASON-STADLER(R), JAEGER(TM), LYRA(R), MEDELEC(R), MICROGAS(R), NAVIGATOR(R), NICOLET(R), NicoletOne(TM), PULMONETIC(TM), SENSORMEDICS(R), TECA(R), TECOMET(TM), VELA(R) and VMAX(R). VIASYS is headquartered in Conshohocken, PA, and its businesses are conducted through its Respiratory Care, NeuroCare, MedSystems and Orthopedics business units. More information can be found at www.viasyshealthcare.com.
Contact:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: marian.robinson@baxa.com
Source: Baxa Corporation
Web site: www.baxa.com/
http://www.viasyshealthcare.com/
